A phase 2 randomized double-blind placebo-controlled study to evaluate safety of BLD-2660 and its activity against COVID-19 virus in hospitalized subjects recently diagnosed with COVID-19 in comparison to standard of care treatment : A phase 2 randomized double-blind placebo-controlled study to evaluate safety and antiviral activity of BLD-2660 in hospitalized subjects with recently diagnosed COVID-19 compared to standard of care treatment

Medienart:

Klinische Studie

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

WHO International Clinical Trials Registry Platform - (2023) vom: 29. Mai Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: new coronavirus infection; viral pneumonia, not elsewhere classified;C01.925.782.600.550.200
Recruitment Status: Recruiting
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 26-08-2020, Last updated: 2023-06-05

ICTRP ID:

RBR-2kjm6y

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

WHO00455180X